Abiding its time

Celgene option deal buys Abide time to validate platform, expand target space

Abide Therapeutics Inc.'s option deal with Celgene Corp. gives it several years to validate its serine hydrolase platform. Should Celgene opt to license ex-U.S. rights to Abide's lead inflammation programs rather than buy the company - or even if Celgene does neither - Abide will come away with a more mature platform and a head start on a handful of programs.

Alan Ezekowitz, president and CEO of Abide, said the

Read the full 698 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE